Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series

Abstract Objective To capitalize on data from different clinical series to compare sensitivity and specificity of individual biomarkers for predicting mild cognitive impairment (MCI) progression to Alzheimer's disease (AD). Methods Medial temporal atrophy, cortical hypometabolism, and cerebrosp...

Full description

Saved in:
Bibliographic Details
Published in:Alzheimer's & dementia 2013-11, Vol.9 (6), p.677-686
Main Authors: Prestia, Annapaola, Caroli, Anna, Herholz, Karl, Reiman, Eric, Chen, Kewei, Jagust, William J, Frisoni, Giovanni B
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Alzheimer Disease - diagnosis
Alzheimer's disease
Amyloid beta-Peptides - cerebrospinal fluid
Biological markers
Biomarkers - analysis
Cognition Disorders - cerebrospinal fluid
Cognition Disorders - complications
Cognition Disorders - diagnosis
Conversion
Databases, Factual - statistics & numerical data
Diagnostic accuracy
Diagnostic test assessment
Disease Progression
Female
Fluorodeoxyglucose F18
Hippocampus - diagnostic imaging
Hippocampus - pathology
Humans
Magnetic Resonance Imaging
Male
MCI
Memory
Middle Aged
MRI
Neuroimaging
Neurology
Peptide Fragments - cerebrospinal fluid
PET
Positron-Emission Tomography
Sensitivity
Sensitivity and Specificity
Statistics, Nonparametric
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective To capitalize on data from different clinical series to compare sensitivity and specificity of individual biomarkers for predicting mild cognitive impairment (MCI) progression to Alzheimer's disease (AD). Methods Medial temporal atrophy, cortical hypometabolism, and cerebrospinal fluid biomarkers were assessed in 18 patients with mild cognitive impairment (MCI) with prodromal AD (pAD; conversion time, 26 ± 12 months) and 18 stable MCI (sMCI) patients from the Translational Outpatient Memory Clinic cohort, as well as in 24 pAD patients (conversion time, 36 ± 12 months) and 33 sMCI patients from the Alzheimer's Disease Neuroimaging Initiative cohort. Medial temporal atrophy was measured by manual, semi-automated, and automated hippocampal volumetry; cortical hypometabolism was measured using several indices of AD-related hypometabolism pattern; and cerebrospinal fluid markers were amyloid β (Aβ)42 and total tau protein concentrations. For each biomarker, sensitivity for pAD, specificity for sMCI, and diagnostic accuracy were computed. Results Sensitivity to predict MCI conversion to AD in the Alzheimer's Disease Neuroimaging Initiative and Translational Outpatient Memory Clinic cohorts was 79% and 94% based on Aβ42, 46% and 28% based on hippocampal volumes, 33% to 66% and 56% to 78% based on different hypometabolism indices, and 46% and 61% based on total tau levels, respectively. Specificity to exclude sMCI was 27% and 50% based on Aβ42, 76% and 94% based on hippocampal volumes, 58% to 67% and 55% to 83% based on different hypometabolism indices, and 61% and 83% based on total tau levels, respectively. Conclusions Current findings suggest that Aβ42 concentrations and hippocampal volumes may be used in combination to best identify pAD.
ISSN:1552-5260
1552-5279
DOI:10.1016/j.jalz.2012.09.016